CUE - Cue Biopharma, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD

Cue Biopharma, Inc.

21 Erie Street
Cambridge, MA 02139
United States
617-949-2680
http://www.cuebiopharma.com

SectorHealthcare
IndustryBiotechnology
Full-time employees45

Key executives

NameTitlePayExercisedYear born
Mr. Daniel R. Passeri M.Sc., MSc., J.D.CEO & Director452.69kN/A1961
Dr. Anish Suri Ph.D.Pres & Chief Scientific Officer471.38kN/A1973
Mr. Colin G. Sandercock J.D., M.Sc.Sr. VP, Gen. Counsel & Sec.330.22kN/A1957
Dr. Steven C. AlmoCo-Founder and Chairman of Scientific & Clinical Advisory BoardN/AN/A1961
Ms. Kerri-Ann MillarVP of Fin. and Principal Accounting & Fin. OfficerN/AN/A1969
Amounts are as of 31 December 2018, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cue Biopharma, Inc., a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, a non-viral antigen for cancers; CUE-103, an antigen; CUE-200 framework that includes CD80 and/or 4-1BBL to reactivate exhausted T cells and design to enhance antigen-specific T cell for the treatment of chronic infectious diseases; and CUE-300 framework to target various autoimmune diseases. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for Immuno-selective targeting and alteration of T cells (STAT) in the field of oncology; and Albert Einstein College of Medicine to develop Immuno-STAT biologics for chronic infectious diseases. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Cue Biopharma, Inc.’s ISS governance QualityScore as of 4 December 2019 is 8. The pillar scores are Audit: 2; Board: 9; Shareholder rights: 5; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.